Compared to the other trials investigating GLP-1RAs, the ELIXA trial included T2D patients with recent acute coronary syndrome (ACS), suggesting that perhaps their CV risk was too severe to demonstrate a simple decline in CV events via short-term pharmacological intervention
If you are concerned about how stopping GLP-1 medication might affect your eating, or if you have noticed that your relationship with food has become more difficult since starting these medications, we are here to help you find a way through that feels manageable and safe
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
Sajan profoundly cares about the well-being and satisfaction of his patients and uses all of his knowledge and techniques to produce the best results when it comes to weight loss
Key Takeaways: Higher doses lead to greater weight loss but may cause more side effects
A 300 mcg dose would be 12 units
